Evidence map›Paper›PMID 28655925›Full record

ArticleLeukemia2018

Natural history of t(11;14) multiple myeloma.

A Lakshman, M Alhaj Moustafa, S V Rajkumar, A Dispenzieri, M A Gertz, F K Buadi, M Q Lacy, D Dingli, A L Fonder, S R Hayman and 13 more

Abstract read
PubMed Publisher
In one paragraph

Article in Leukemia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 78 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Observational
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. High or low? Assessing disease risk in multiple myeloma.Hematology. American Society of Hematology. Education Program · 2022
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 2 institutions in 1 country.

A LakshmanDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0001-8915-2382
M Alhaj MoustafaInternal Medicine, MedStar Washington Hospital Center, Washington, DC, USA.
S V RajkumarDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
A DispenzieriDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
M A GertzDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
F K BuadiDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
M Q LacyDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
D DingliDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
A L FonderDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
S R HaymanDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
M A HobbsDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
W I GonsalvesDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
Y L HwaDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
P KapoorDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
N LeungDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0002-5651-1411
R S GoDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
Y LinDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
T V KourelisDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
J A LustDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
S J RussellDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
S R ZeldenrustDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
R A KyleDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
S K KumarDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
Mayo Clinic · USMedStar Washington Hospital Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Translocation (11;14) on interphase fluorescent in situ hybridization in plasma cells is regarded as a standard risk prognostic marker in multiple myeloma based on studies conducted before introduction of current therapies. We identified 365 patients with t(11;14), and 730 matched controls:132 patients with non-(11;14) translocations and 598 patients with no chromosomal translocation. The median progression-free survival for the three groups were 23.0 (95% confidence interval (CI), 20.8-27.6), 19.0 (95% CI, 15.8-22.7) and 28.3 (95% CI, 25.7-30.6) months, respectively (P<0.01). The median overall survival (OS) for t(11;14), non-(11;14) translocation and no-translocation groups were 74.4 (95% CI, 64.8-89.3), 49.8 (95% CI, 40.0-60.6) and 103.6 (95% CI, 85.2-112.3) months, respectively (P<0.01). Excluding those with 17p abnormality, the median OS in the three groups were 81.7 (95% CI, 67.0-90.7), 58.2 (95% CI, 47.0-76.4) and 108.3 (95% CI, 92.4-140.1) months, respectively (P<0.01). The above relationship held true in patients with age <65 years, international staging system (ISS) I/II stage or those who received novel agent-based induction. Advanced age (hazard ratio (HR): 1.98), 17p abnormality (HR: 2.2) and ISS III stage (HR: 1.59) at diagnosis predicted reduced OS in patients with t(11;14). These results suggest that outcomes of t(11;14) MM are inferior to other standard risk patients.

Indexed as

AdultAgedAged, 80 and overChromosome AberrationsChromosomes, HumanFemaleHumansIn Situ Hybridization, FluorescenceMaleMiddle AgedMultiple MyelomaNeoplasm StagingPrognosisProgression-Free SurvivalTranslocation, GeneticYoung Adult

Identifiers

PMID28655925
OpenAlexW2732274389

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.